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Intimin, the product of the eaeA gene in enterohemorrhagic Escherichia coli O157:H7 (EHEC), is required for
intimate adherence of these organisms to tissue culture cells and formation of the attaching and effacing lesion
in the gnotobiotic pig. Because of the importance of intimin in the pathogenesis of EHEC O157:H7 infection
in this animal model, we began a structure-function analysis of EaeA. For this purpose, we constructed
amino-terminal fusions of the intimin protein with six histidine residues to form two independent fusions. The
longer fusion, RIHisEae, contained 900 of the 935 predicted amino acids and included all but the extreme
amino terminus. The second fusion, RVHdHisEae, consisted of the carboxyl two-thirds of the protein. Purified
extracts of either construct enhanced binding of wild-type 86-24 to HEp-2 cells and conferred HEp-2 cell
adherence on 86-24eaeD10, an eaeA deletion mutant, and B2F1, an EHEC O91:H21 eaeA mutant strain. When
86-24eaeD10 was transformed with either of the plasmids encoding the intimin fusion proteins, the transformant behaved like the wild-type parent strain and displayed localized adherence to HEp-2 cells, with positive
fluorescent-actin staining. In addition, polyclonal antisera raised against RIHisEae reacted with both fusion
constructs and recognized an outer membrane protein of the same mass as intimin (97 kDa) in EHEC and
enteropathogenic E. coli but not E. coli K-12. The intimin-specific antisera also blocked adherence of EHEC to
HEp-2 cells. Thus, intimin (i) is a 97-kDa outer membrane protein in EHEC that serves as a requisite adhesin
for attachment of the bacteria to epithelial cells, even when the protein is truncated by one-third at its amino
terminus and (ii) can be added exogenously to specifically facilitate HEp-2 cell adherence of EHEC but not E.
coli K-12.

EHEC O157:H7 strains react with antisera to the 94-kDa protein. Second, Sherman et al. (41) reported that antibodies that
recognize the 94-kDa OMP block adherence of EHEC strains
to epithelial cells in culture, but these same antibodies do not
recognize intimin (6). That none of the factors described above
are capable of conferring epithelial cell adherence when transformed independently into an E. coli K-12 background suggests that multiple EHEC determinants are required for adherence of the organism to epithelial cells in culture.
Although the mechanism(s) by which EHEC attach to the
intestinal epithelium and cause the A/E lesion are not fully
understood, we have shown that intimin is one essential component for attachment of EHEC O157:H7 strains to epithelial
cells in culture and for formation of the A/E lesion in vivo (5,
29). Specifically, we demonstrated that an in-frame mutation in
the eaeA locus of EHEC strain 86-24 (O157:H7) ablates HEp-2
cell adherence and A/E lesion formation in the gnotobiotic
piglet. Full adherence and fluorescent-actin staining (FAS)
activity is restored to the mutant by transformation with a
plasmid that encodes the wild-type copy of eaeA (29). Because
of this critical role for the eaeA gene product of EHEC
O157:H7 in the initial steps of EHEC pathogenesis, we sought
to begin an examination of the relationship between intimin
structure and its function as an adhesin.
In the present study, six histidine (6/X/His) residues were
fused to the amino terminus of intimin to create two independent truncated fusion proteins. These fusion proteins were
used as tools to begin to define the mechanisms by which
intimin promotes EHEC adherence to epithelial cells.

Enterohemorrhagic Escherichia coli (EHEC) is responsible
for a spectrum of illnesses in humans, including nonbloody
diarrhea, hemorrhagic colitis (HC), and the hemolytic uremic
syndrome (36, 45). EHEC is recognized as the leading cause of
infectious bloody diarrhea in the United States as well as acute
renal failure among U.S. and Canadian children (3). The primary characteristics of EHEC that have been linked to the
organism’s virulence are (i) production of the Shiga-like toxins
(reviewed in references 33 and 46), (ii) presence of the 60MDa plasmid (9, 18, 19, 47, 50), and (iii) the capacity to
produce an attaching and effacing (A/E) intestinal lesion in
experimental animals (7, 35, 49).
Several bacterial components have been implicated in intimate adherence of EHEC to epithelial cells and the capacity of
the organism to cause the A/E lesion in vivo. These factors
include (i) a product(s) of the aforementioned 60-MDa plasmid (termed pO157 in reference 47); (ii) a 94-kDa outer membrane protein (OMP) required for EHEC adherence to Henle
407 cells (41, 42); (iii) intimin, the product of the chromosomal
eaeA gene (5, 6, 29); and (iv) products of two genes that have
been insertionally inactivated by TnphoA (6). Evidence that
the first three components are distinct is as follows. First,
Dytoc et al. (6) demonstrated that the factor(s) encoded by
pO157 is different from the chromosomally encoded eaeA
product and the 94-kDa OMP by showing that plasmid-cured
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TABLE 1. Strains and plasmids used in this study
E. coli strain or
plasmid

Strains
86-24
B2F1
86-24eaeD10
EDL933
933cu
E2348/69
DH5a
XL1-Blue
M15
SG13009
2442
2443
HS
Plasmids
pEB310

pQE32
pEB312
pEB313
pQE16
pREP4

Relevant characteristic(s)

Wild-type EHEC
O157:H7
Wild-type EHEC
O91:H21
86-24 eaeA deletion
mutant
Wild-type O157:H7
Plasmid-cured derivative
of EDL933
Wild-type EPEC
O127:H6
Cloning host, adherencenegative control
Cloning host
Expression host
Expression host
O82 (rough)
O81 (smooth)
Nonpathogenic normalflora isolate, O9:H4
PCR-derived eaeA clone
from EHEC 86-24 in
pBRKS2 in
orientation of PT7
Histidine fusion cloning
vector
6XHis::eaeA, source of
RVHdHisEae
6XHis::eaeA, source of
RIHisEae
6XHis::dhfrs, source of
HisDHFR
lacIq

Source (reference)

P. Tarr (11)
B. Rowe (16)
29
K. Wachsmuth (37)
19
24
BRL
Stratagene
Qiagen
Qiagen
32
31
24

29

Qiagen
This study
This study
Qiagen
Qiagen

MATERIALS AND METHODS
Cells, bacterial strains, and plasmids. HEp-2, human laryngeal epithelial cells
(ATCC CCL23), and HCT-8, human ileocecal epithelial cells (ATCC CCL244),
were obtained from the American Type Culture Collection, Rockville, Md.
Eukaryotic cell cultures were maintained by serial passage in complete Eagle’s
minimal essential medium (EMEM) (BioWhittaker, Walkersville, Md.) (10%
fetal calf serum, 20 mM L-glutamine, 100 mg of gentamicin per ml, 100 U of
penicillin G).
The bacterial strains and plasmids used in this study are described in Table 1.
EHEC O157:H7 strain 86-24 was isolated in 1986 from a patient in Seattle,
Wash. (11). Strain 933 (EHEC O157:H7) was isolated from a patient in the 1982
outbreak of HC (37). E. coli K-12 strain DH5a (Bethesda Research Laboratories, Gaithersburg, Md.) was used as a negative control in the adherence assays.
The eaeA gene from 86-24 was cloned into plasmid vector pBRKS2 (40). Briefly,
pBRKS2 is a pBR328-based vector that includes the multicloning site from
pBluescriptKS2 (Stratagene) as well as the promoter of b-galactosidase (Plac) in
one orientation and the T7 phage promoter (PT7) in the opposite orientation
(40). The cloning vectors used to construct the histidine-intimin fusion proteins
were obtained from Qiagen, Inc. (Chatsworth, Calif.). The fusion constructs were
expressed in an M15 or SG13009 background which had been transformed with
pREP4 (described in Table 1).
Media, enzymes, biochemicals, and radionuclides. Bacterial strains were routinely grown on Luria broth (LB) (10 g of tryptone, 5 g of yeast extract, 5 g of
sodium chloride) or MacConkey (Difco Laboratories, Detroit, Mich.) or LB
agar. When appropriate, antibiotics (Sigma Chemical Co., St. Louis, Mo.) were
added to the medium at the following final concentrations: ampicillin, 100 mg/ml;
chloramphenicol, 20 mg/ml; kanamycin, 25 mg/ml; and tetracycline, 12.5 mg/ml.
These concentrations were occasionally varied for a specific assay. To screen
clones that contained DNA inserts which inactivated b-galactosidase, the gratuitous inducer of the lac operon, IPTG (isopropyl-b-D-thiogalactopyranoside) and
the colorimetric substrate X-Gal (5-bromo-4-chloroindolyl-b-D-galactoside)
were added at 100 mM and 20 mg/ml, respectively, to solidified LB agar. Restriction endonucleases and calf intestinal alkaline phosphatase were purchased

from Bethesda Research Laboratories, Boehringer Mannheim Biochemicals (Indianapolis, Ind.), or New England BioLabs (Beverly, Mass.). Enzymes were used
according to the particular manufacturer’s instructions unless otherwise stated.
Radionuclides were purchased from New England Nuclear Research Products
(Boston, Mass.).
DNA manipulations. Cloning procedures and plasmid manipulations were
carried out essentially according to the procedures described by Maniatis et al.
(27). Plasmid DNA was isolated by alkaline lysis (27) for screening or by use of
Qiagen plasmid isolation columns (Qiagen, Inc.) for large-scale preparations.
Plasmids were moved into the appropriate host strains by CaCl2 transformation
(26) or electroporation (43).
Adherence assays. Adherence of E. coli to either HEp-2 or HCT-8 cells was
assessed by a modification of the method of Cravioto et al. (4) that was described
earlier (30). Only results with the HEp-2 cells are presented, but similar adherence data were obtained with the HCT-8 cells. The extent and phenotype of
adherence of a particular bacterial strain to these cells were assessed by microscopic observation rather than quantitative bacterial counts because in preliminary studies the former method was a more sensitive estimate of phenotypic
difference between strains.
To assess the effect of anti-intimin antibodies on EHEC adherence, mouse or
rabbit anti-intimin antisera (or preimmune sera as controls) were added to the
bacteria suspended in 1 ml of adherence medium, and the bacterium-antiserum
mixture was incubated at 378C for 30 min prior to infection of the HEp-2 cells.
Antisera were present in the adherence medium throughout the assay. To evaluate the effect of exogenously added intimin fusion proteins on bacterial HEp-2
cell adherence, the purified His-intimin fusion protein was diluted in adherence
assay medium and added to the epithelial cell monolayer. The HEp-2 cells were
incubated in the presence of the fusion protein for 30 min at 378C prior to the
addition of bacteria. The presence of the fusion protein was maintained throughout the standard 6-h adherence assay. In separate experiments, the bacteria were
preincubated with the fusion protein before addition to the HEp-2 cell monolayer. The results were indistinguishable whether the fusion protein was maintained in the medium or preincubated with the bacteria. Other specific manipulations of the adherence assay are discussed in Results.
Expression and visualization of native intimin proteins. The eaeA gene was
cloned into vector pBRKS2 in the orientation of the T7 RNA polymerasedependent promoter (PT7) to allow expression of the eaeA gene product as
described by Tabor and Richardson (44). Proteins encoded by pEB310 and
under PT7 control were selectively expressed in DH5a which contained plasmid
pGP1-2, a plasmid that encodes a temperature-inducible copy of the T7 RNA
polymerase (44). The protein products were pulse-labeled with [35S]methionine,
and whole-cell lysates or fractionated cell components were separated by discontinuous denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 4% stacking gel with 10% separating gel) (20) on a Mini
Protean II slab cell apparatus according to the instruction manual provided by
the manufacturer (Bio-Rad). Proteins that had incorporated the [35S]methionine
were visualized by autoradiography.
Expression and purification of His-intimin fusion proteins. To construct
RIHisEae, the EcoRI-HindIII fragment from pEB310 (29), which includes most
of the eaeA gene, was inserted into the SmaI-HindIII sites of vector pQE32.
Specifically, the sticky end generated by EcoRI digestion of pEB310 was filled in
with nucleotides to create a blunt end which, in turn, was ligated into the SmaI
site of pQE32. The construct that expressed RVHdHisEae was created by ligation of the EcoRV-HindIII fragment from pEB310 into the SmaI-HindIII sites of
pQE32. The His-intimin fusion proteins were expressed (as described below),
denatured with urea according to the manufacturer’s protocol, and purified to
homogeneity over Ni-NTA resin (nickel-nitrilotriacetic acid agarose) (Qiagen, Inc.) as shown schematically in Fig. 1. For large-scale purification of the
His-intimin fusions, log-phase cultures (0.25 to 1 liter) of either E. coli
MG15(pREP4, pEB312) or E. coli MG15(pREP4, pEB313) in LB were induced with 0.1 mM IPTG for 2 h at 378C with vigorous shaking and the
bacteria were harvested by centrifugation. Bacterial cells that expressed the
His-intimin fusion proteins were lysed by addition of 5 ml of buffer A (6 M
guanidine hydrochloride, 0.1 M NaH2PO4, 0.01 M Tris [pH 8.0]) per g (wet
weight) of the bacterial pellet and gently stirred for 1 h at room temperature.
The slurry was centrifuged at 10,000 3 g for 15 min at 48C to remove bacterial
debris. The supernatant was mixed with 2 ml of Ni-NTA resin preequilibrated
in buffer A and gently stirred at room temperature. The resin was washed
twice with buffer A and then loaded into a 1.6-cm-diameter column. The
column was washed extensively with buffer B (8 M urea, 0.1 M NaH2PO4, 0.01
M Tris [pH 8.0]) and then multiple times with buffer C (buffer B at pH 6.3).
To determine the protein content of the washes, the A280 of column fractions
was monitored. One-milliliter fractions of the fusion proteins were eluted in
buffer C supplemented with 250 mM imidazole. Samples of the eluted fractions that contained the fusion protein were separated by SDS–10% PAGE,
and the protein bands were visualized by Coomassie blue staining of the gel.
Urea was removed from the eluted fractions, and the proteins were renatured
by exhaustive dialysis against 10 mM phosphate-buffered saline (PBS), pH
7.4.
For the small-scale purification procedure, 25-ml cultures of E. coli
MG15(pREP4) that contained either plasmid pEB312, pEB313, or pQE16 were
induced with 0.1 mM IPTG, and the expressed fusion proteins were processed as
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FIG. 1. (A) Purified His-intimin fusion proteins were separated by SDS-PAGE and stained with Coomassie blue. RIHisEae is 101 kDa, and RVHdHisEae is 65
kDa. (B) Autoradiograph of the [35S]methionine-labeled product of the EHEC eaeA locus expressed from the T7 RNA polymerase-dependent promoter. Lane 1,
DH5a(pGP1-2, pBRKS2); lane 2, 14C-labeled carbonic anhydrase marker (Mr 5 97,400); lane 3, DH5a(pGP1-2, pEB310). The large arrow points to the doublet
thought to be intimin; the smaller arrow indicates a minor degradation product of intimin at Mr 5 80,000.

recommended by the manufacturer’s instructions over Ni-NTA spin columns
(Qiagen). Approximately 100 to 200 mg of either RVHdHisEae, RIHisEae, or
His:DHFRS per ml, respectively, was obtained by this small-scale purification
method.
Immunization of mice and rabbits. Four female BALB/cJ mice (Jackson
Laboratory, Bar Harbor, Maine) were prebled and then injected intraperitoneally with 25 mg of RIHisEae fusion protein in TiterMax adjuvant (Vaxcel, Inc.,
Norcross, Ga.) three times over a 6-week period. Blood samples were obtained
by nicking the tail veins of the mice. When the serum sample from each mouse
contained a high titer of anti-intimin antibodies, all animals were sacrificed by
exsanguination and the sera were collected.
Two male New Zealand White rabbits (HRP, Inc., Denver, Pa.) were injected
intramuscularly at four sites with 100 mg (total) of RIHisEae in TiterMax and
then given two booster injections with 100 mg of the protein per ml in PBS at
3-week intervals. Anti-intimin antibody titers of the mouse or rabbit antisera
were assessed by the enzyme-linked immunosorbent assay (ELISA) described
below.
ELISA to detect anti-intimin antibodies. Fifty nanograms of RIHisEae (or
RVHdHisEae, where specified) was plated onto polystyrene 96-well microtiter
plates as an antigen substrate to test the reactivity of rabbit or mouse sera against
intimin. After an overnight incubation at 48C, the coated plates were washed with
PBS and unoccupied sites on the wells were blocked with 3% bovine serum
albumin in 10 mM PBS, pH 7.4. Two-hour incubations with primary and secondary antibodies (either horseradish peroxidase-conjugated goat anti-mouse
[Boehringer Mannheim Biochemicals] or donkey anti-rabbit [Amersham Corp.,
Arlington Heights, Ill.] when appropriate] were carried out at room temperature
with PBS washes between each step. TMB (39,39,59,59-tetramethylbenzidine)
peroxidase (Bio-Rad) was added to each well as the substrate. After 10 to 30 min
of incubation, the enzymatic reaction was terminated by the addition of 1 N
H2SO4, which caused the mixture to turn yellow. The intensity of the yellow color
was monitored on a Titertek Multiscan MC microliter plate reader (Flow Laboratories, McLean, Va.). The optical density values were plotted for each sample.
The anti-intimin titer was defined as an A450 value 0.2 U above the negative
control value, which was usually the value obtained with normal sera.
Bacterial membrane fractionation. Bacterial membrane fractionation was
done essentially according to the method of Achtman et al. (1). Overnight
cultures of bacteria were subcultured into fresh LB for 2 h at 378C. Pelleted
bacteria were resuspended in 10 mM Tris with 100 mg of PMSF (phenylmethylsulfonyl fluoride) per ml and sonically disrupted. The bacterial lysates were
subjected to low-speed centrifugation to remove intact cells, and the resultant
supernatant was centrifuged at 100,000 3 g for 1 h to harvest the bacterial
membranes. OMPs were extracted by precipitation with 1.67% sarcosyl in 11.1
mM Tris, pH 7.6, at room temperature and then pelleted by centrifugation at
48C. The sarcosyl precipitate was solubilized in Tris-PMSF, quantitated by the

Bradford method (BCA Quantification Kit; Pierce), and subjected to SDSPAGE followed by immunoblot analysis (described below).
Immunoblotting. Proteins separated by SDS-PAGE were electroblotted onto
nitrocellulose according to the method of Towbin et al. (48). The membranes
were blocked with 5% nonfat dried milk (Carnation Company, Los Angeles,
Calif.) in Tris-buffered saline, pH 7.2, with 0.1% (vol/vol) Tween 20 (TBS-T),
washed, and then incubated with either mouse or rabbit anti-intimin serum (the
concentration of antiserum is indicated in each experiment). The membranes
were washed three times with TBS-T and then overlaid with a 1:5,000 dilution of
either horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
(Boehringer Mannheim Biochemicals), donkey anti-rabbit immunoglobulin
(Amersham), or sheep anti-human immunoglobulin (Amersham). Antigen-antibody complexes were visualized by chemiluminescence with the ECL Western
blotting (immunoblotting) detection kit (Amersham).
Agglutination tests. The capacity of the purified fusion proteins to agglutinate
wild-type EHEC (either 10 ml of a saturated broth culture or a single colony from
an agar plate) was tested by mixing 5 mg of purified fusion protein with E. coli
O157:H7 strain 86-24. The capacities of antisera raised against the intimin fusion
proteins to agglutinate EHEC strain 86-24 were assessed by slide agglutination
tests with neat sera or sera diluted 1:10 in PBS. Agglutination with rabbit
anti-O157:H7 sera (Difco) was used to confirm the serotype of E. coli O157:H7
strains used throughout this study.

RESULTS
Expression of the eaeA product under control of the T7
promoter. We first sought to evaluate EHEC intimin at the
protein level by analysis of the native protein. Plasmid pEB310
contains the wild-type eaeA locus cloned from EHEC O157:H7
strain 86-24 in an orientation such that the T7 RNA polymerase-dependent promoter (PT7) can drive transcription of
the gene (the construction of pEB310 was previously described
in reference 29). The intimin protein encoded by pEB310 was
overexpressed in a background that included a temperatureinducible copy of the T7 RNA polymerase gene on plasmid
pGP1-2. Three major products of the cloned insert were observed (Fig. 2). The major bands were a doublet at 97 kDa and
a singlet at approximately 80,000 Da. The majority of the
intimin expressed by this method remained associated with the
bacterial membrane fraction even after sonic disruption of the
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FIG. 2. (A) Reactivity of mouse anti-intimin antibodies (1:2,500) against intimin expressed from plasmid pEB310. Lane 1, DH5a(pGP1-2, pBRKS2) membraneassociated fraction; lane 2, DH5a(pGP1-2, pEB310) supernatant fraction from sonically disrupted cells; lane 3, DH5a(pGP1-2, pEB310) membrane-associated fraction.
The arrow indicates the 97-kDa protein, intimin. (B and C) Immunoblots of mouse anti-intimin antisera against bacterial fractions from wild-type 86-24, the eaeA
mutant with and without plasmid pEB310, or the K-12 strain XL1-Blue. Lanes: 1 and 5, low-speed supernatant; 2 and 6, high-speed supernatant; 3 and 7, high-speed
pellet fraction; 4 and 8, sarcosyl precipitate from the high-speed pellet. Molecular weight markers (in thousands) are to the left; the arrow indicates intimin.

host bacterium and addition of mild detergent to the extraction
buffer.
Construction and purification of intimin fusion proteins.
The insolubility of the intimin protein, combined with the
abundance of other native E. coli protein species in the 97-kDa
range (as seen by Coomassie blue staining of such proteins
separated by SDS-PAGE gels [data not shown]), made purification of the native protein difficult. For these reasons, we
sought a fusion protein approach for rapid and easy purification of intimin. The 6XHis fusion protein system of Qiagen,
Inc., was chosen to create His-intimin fusions because (i) a
small peptide is added to the amino-terminal end of the protein rather than a bulky protein like the maltose binding protein (MBP); (ii) the 6XHis tag binds tightly to a nickel affinity
matrix, which facilitates one-step purification of the fusion
protein for further studies; and (iii) the expression system is
designed to maintain tight control of the 6XHis fusion proteins
to prevent any possible lethal effects of the recombinant protein on the E. coli host strain.
Two fusions were constructed as outlined in Materials and
Methods. The longer fusion, RIHisEae, was ;101 kDa and
encoded 900 of 935 predicted amino acids (Fig. 1). This construction resulted in an in-frame fusion of the 6XHis tag with
intimin that had been truncated by 35 amino acids at its amino
terminus. These 35 residues were deleted to remove any po-

tential signal sequence that might lead to cleavage of the His
tag from the intimin. Such a possibility is suggested by analogy
with the mature intimin from EPEC E2348/69, which begins 39
residues from the first methionine residue and, thus, appears to
be cleaved or processed (10). The shorter fusion, RVHdHisEae,
was ;65 kDa and encoded 604 amino acids of the carboxyl twothirds of the wild-type intimin protein. As with the PT7-expressed
intimin, each of the fusion proteins remained primarily in the
insoluble pellet after sonic disruption of the host E. coli (data
not shown). Therefore, 8 M urea was included in all of the
extraction buffers to allow solubilization of the fusion proteins
from the pellet. Both His-intimin fusion constructs were purified to homogeneity over nickel affinity columns (Fig. 1). Neither of the fusion proteins agglutinated wild-type 86-24 (data
not shown).
Antisera to His-intimin fusion proteins. Intimin-specific antibodies were produced in both mice and rabbits that had been
immunized with purified RIHisEae fusion protein. The antiEae antibody titers for all sera were high (.10,000 for the
rabbit sera and 1,300 to 5,000 for the mouse sera). The antisera
raised in mice and rabbits recognized both fusion proteins by
Western blotting (data not shown) as well as intimin expressed
under the control of the T7 promoter in pEB310 (representative mouse anti-intimin serum data are shown in Fig. 3A).
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FIG. 3. Microcolonies (indicated by the arrows) exhibited by wild-type 86-24 on HEp-2 cells in the presence of 20 ng of the histidine fusion protein. (A) One
microscopic field with FAS; (B) the same field viewed by phase microscopy. In the presence of 2 mg (C) (phase contrast) or 20 mg (D) (phase contrast) of RIHisEae,
microcolonies (indicated by the arrowheads) were larger and a greater proportion of the HEp-2 cell surface was covered by bacteria.

Prebleed sera from the mice and rabbits did not recognize the
fusion proteins (immunoblot not shown).
Recognition of 97-kDa bacterial OMP by anti-intimin sera.
Antibodies to the intimin fusion protein raised in mice recognized a 97-kDa protein in the sarcosyl-insoluble fraction of
extracts from 86-24 and 86-24eaeD10(pEB310) (Fig. 3B and
C). An OMP of approximately 97 kDa expressed by EHEC
O157:H7 strains 933 and 933cu as well as by EPEC strain
E2348/69 reacted with anti-intimin sera (data not shown). The
mouse anti-intimin sera did not recognize any proteins in outer
membrane extracts from the E. coli K-12 XL-1Blue (Fig. 3C)
or the O91:H21 eaeA mutant isolate, B2F1 (data not shown),
that were unique to these strains. From these data, we conclude that EHEC intimin is a 97-kDa OMP expressed by bacterial strains that carry the eaeA locus and that the intimins
expressed by EHEC and EPEC are immunologically related.
The anti-intimin sera also recognized a smaller-molecularweight protein in the fraction of bacteria that included both the
cytoplasmic and periplasmic contents. This 50-kDa species was
present only in preparations that had been stored at 48C or
those preparations that had gone through at least one freezethaw cycle. Therefore, we believe that this 50-kDa protein is a
degradation product of RIHisEae.

Recognition of EHEC proteins by HC patient sera. Tested
convalescent-phase immune sera from HC patients (n 5 4;
kindly provided by T. Barrett, Centers for Disease Control and
Prevention, Atlanta, Ga.) reacted with PT7-expressed intimin
as well as other E. coli proteins in a Western immunoblot (data
not shown). To decrease reactivity of the HC patients’ sera
with nonintimin E. coli proteins contained in the expression
system, samples of sera were adsorbed with whole-cell extracts
of DH5a transformed with pGP1-2 and pBRKS2 (the expression system). After adsorption, the convalescent-phase HC
patient sera recognized intimin and a few other E. coli proteins
but no longer reacted with proteins expressed from pEB310
other than intimin or the vector control (data not shown).
Commercially available pooled normal human sera also recognized RIHisEae, but two other individual samples of naive
human sera did not. These findings suggest that intimin-expressing bacteria may infect a higher portion of individuals
than is currently recognized.
Blocking of HEp-2 cell adherence by anti-intimin antibodies. The anti-intimin antibodies raised in mice blocked adherence of strain 86-24 to HEp-2 cells in a dilution-dependent
manner when preincubated with the bacteria for 30 min prior
to the infection of the monolayer (data not shown). At a
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FIG. 4. Histidine-intimin fusion proteins render mutant 86-24eaeD10 adherent to HEp-2 cells. Adherence assays with the in-frame deletion mutant strain conducted
in the presence of 1 mg of RIHisEae (A) or 2 mg of RVHdHisEae (B) resulted in microcolony formation by the bacteria. (C) EHEC O91:H21 strain B2F1 was rendered
adherent to HEp-2 cells in the presence of 2 mg of RVHdHisEae. (D) The E. coli K-12 control strain DH5a failed to bind HEp-2 cells in the presence of 1 mg of
RIHisEae.

1:1,000 dilution of the anti-intimin sera, partial blocking of
bacterial adherence was observed. As the concentration of
anti-intimin antibodies increased to a 1:10 dilution, total blocking of EHEC 86-24 adherence to HEp-2 cells was achieved.
With preimmune sera, partial interference with adherence was
seen at dilutions up to 1:100. Neither the mouse nor the rabbit
anti-intimin sera agglutinated wild-type 86-24 when tested neat
or diluted 1:10 (data not shown).
Adherence of wild-type EHEC in the presence of His-intimin
fusion proteins. Both of the fusion proteins were tested for the
capacity to block binding of 86-24 to HEp-2 or HCT-8 cells in
vitro. We hypothesized that if intimin acts as a primary EHEC
adhesin, then preincubation of the eukaryotic cells with excess
His-intimin should occupy most or all of the receptor binding
sites available on the HEp-2 cell surface for intimin. This
hypothetical receptor saturation should block further adherence by the wild-type bacteria. To test this theory, we incubated HEp-2 cell monolayers with 20 ng to 20 mg of RIHisEae
for 30 min prior to the addition of 86-24. The presence of the
fusion protein was maintained throughout at least the first 3 h
of the adherence assay. At the end of 6 h, the infected monolayers were washed extensively, stained with fluorescein iso-

thiocyanate-phalloidin, and observed by either phase-contrast
or fluorescence microscopy. The results are presented in Fig. 4.
Contrary to our expectation that the fusion proteins would
block adherence, the fusions enhanced binding of EHEC 86-24
to HEp-2 cells. The size of the EHEC 86-24 microcolony as
well as the total number of HEp-2 cells with adherent microcolonies increased as the concentration of RIHisEae increased. A similar amino-terminal fusion of six histidine residues to mouse dihydrofolate reductase (His-DHFR) did not
enhance the adherence of 86-24. At high doses (20 to 200 mg),
both the fusion protein and the control His-DHFR caused the
HEp-2 cells to show aberrant appendages and processes which
were FAS positive even in the absence of bacteria (data not
shown). Therefore, we chose 1 to 2 mg of the fusion proteins as
the optimal dose for further studies to avoid nonspecific effects
on the cells.
Next, we asked whether the fusion protein-mediated enhancement of adherence of smooth EHEC 86-24 but not rough
E. coli DH5a to HEp-2 cells could be a consequence of the
histidine residues added to the intimin proteins nonspecifically
associating with the lipopolysaccharide (LPS). To test this possibility, an isogenic pair of O8 strains and a normal-flora E. coli
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ment 86-24eaeD10 for localized adherence or FAS (data not
shown).
DISCUSSION

FIG. 5. Model of intimin interaction with the bacterium and the epithelial
cell. Intimin ( ) is depicted as a molecule with distinct ends; one end interacts
with the bacterium (circle), and the other end interacts with the eukaryotic cell
(triangle). (1) Wild-type bacteria express intimin as an OMP. Intimin interacts
with a putative receptor on the eukaryotic cell which results in the condensation
and rearrangement of cytoskeletal components (lines within epithelial cell). (2)
When there is exogenous intimin added (in this studtype eaeA1 EHEC [stippled
ovals]), the LA/FAS phenotype is enhanced. (3) When the his-intimin fusions are
added to EHEC bacteria that do not express intimin (i.e., 86-24eaeD10 or B2F1,
shown here as open ovals), the protein interacts with both the bacterium and the
eukaryotic cell to form a “bridge.” Bridge formation confers the LA phenotype
to 86-24eaeD10 and B2F1 but not the FAS phenotype.

strain (HS, serogroup O9:H4) were assayed in the HEp-2 cell
adherence assay in the presence or absence of exogenous
RIHisEae or RVHdHisEae. Strains 2442 (O82) and 2443
(O81) adhered diffusely to HEp-2 cells in the absence or presence of the His-intimin fusion proteins (data not shown). The
smooth HS strain was nonadherent to HEp-2 cells whether or
not exogenous His-intimin was present (data not shown). Thus,
intimin-promoted HEp-2 cell attachment appears to be independent of the presence or serotype of LPS on the surface of
the infecting bacterium.
Adherence of eaeA-negative strains in the presence of Hisintimin fusion proteins. When added exogenously to HEp-2
cells, RIHisEae and RVHdHisEae complemented the HEp-2cell binding defect of 86-24eaeD10 (Fig. 4). Similar concentrations of RIHisEae were unable to render E. coli K-12 strain
DH5a adherent to HEp-2 cells (Fig. 4). Moreover, the mutant,
86-24eaeD10, became localized adherence (LA)/FAS positive
on HEp-2 cells when transformed with either plasmid pEB312
or pEB313, which encode the His-intimin fusion proteins. The
enhancement with exogenous RIHisEae and RVHdHisEae of
wild-type EHEC adherence to HEp-2 cells and the complementation of 86-24eaeD10 for binding to HEp-2 cells suggest
that intimin is capable of interaction with both the bacteria and
the epithelial cells.
EHEC strain B2F1 (O91:H21, eaeA negative) does not bind
to HEp-2 or HCT-8 cells in an LA/FAS manner and does not
cause the A/E lesion in the gnotobiotic piglet intestine (29).
When B2F1 was preincubated with 2 mg of RVHdHisEae, the
bacteria were rendered adherent to HEp-2 cells; i.e., the B2F1
bacteria were observed singly and in small clusters on the
apical surface of the HEp-2 cells (Fig. 4). However, this adherence did not result in the rearrangement of the eukaryotic
cytoskeleton as assessed by FAS. No B2F1 or 86-24eaeD10
organisms adherent to HEp-2 cells were seen in the presence
of 2 mg of His-DHFR (data not shown). Furthermore, plasmid
pQE16, which encodes the His-DHFR fusion, did not comple-

In this study, we purified EHEC intimin by adding six histidine residues to the amino terminus of truncated forms of the
protein and purified the fusion protein in a single step over a
nickel affinity column. The purified fusion protein was used to
raise antisera that recognized native intimin expressed by
EHEC and enteropathogenic E. coli (EPEC), and the antisera
blocked binding of wild-type EHEC to epithelial cells in culture. Furthermore, we demonstrated that EHEC O157:H7 intimin, a 97-kDa OMP, can mediate binding of EHEC strains to
HEp-2 cells when expressed endogenously (as a native or fusion protein) as well as when added exogenously as a purified
histidine fusion protein. Lastly, we showed that the aminoterminal third of EHEC intimin is not required to mediate
adherence to HEp-2 cells, as evidenced by the complementation of the mutant with construct RVHdHisEae.
One model to explain intimin-mediated EHEC adherence of
wild-type EHEC to HEp-2 cells is shown in Fig. 5. In this
model, the intimin protein acts as a bridge between the bacterium and the epithelial cells with two distinct ends: one that
interacts with the putative receptor on the eukaryotic cell surface and another end that interacts with the outer membrane
of the bacterium. The observation that neither RIHisEae nor
RVHdHisEae agglutinated wild-type 86-24 suggests that intimin does not promote bridge formation between the bacteria.
Therefore, according to our model, addition of RIHisEae to
the 86-24–HEp-2 cell milieu caused the formation of additional bacterial-epithelial cell bridges, which led to larger microcolonies on the HEp-2 cells (Fig. 5, part 2).
When the fusion proteins were added to 86-24eaeD10, a
nonadherent mutant that does not express intact intimin, we
speculate that the fusion proteins stuck to the mutant and
became the bridge to the HEp-2 cells (Fig. 5, part 3). This
adherence-promoting effect was fusion protein concentration
dependent. Consistent with this model, the intimin fusion proteins rendered B2F1, a naturally eaeA-negative EHEC isolate
that does not bind HEp-2 cells in an LA/FAS manner, capable
of binding HEp-2 cells in small clusters. Thus, exogenous
complementation for adherence by the intimin fusion proteins
was EHEC specific. Neither of the fusion proteins altered the
HEp-2 cell adherence phenotype of the non-EHEC E. coli
(e.g., E. coli K-12, normal-flora HS, O81, or O82).
Several possibilities can be proposed to explain the weak or
negative FAS activity observed with both the exogenously complemented deletion mutant and the exogenously complemented B2F1 strain. First, there may have been an imprecise
association of the intimin protein with the bacterium or the
epithelial cell when the protein was added exogenously. Second, the entire intimin molecule may be required for the FAS
phenotype (neither of the fusion proteins described contained
the full predicted amino acid sequence). Third, the lack of FAS
activity may be due to an uncharacterized effect of the histidines on the amino terminus of the intimin protein. Or fourth,
accessory proteins or factors required for FAS activity by the
bacteria may not be present in this O91:H21 strain. The recent
description of the LEE locus of A/E bacterial species (28)
supports the latter hypothesis. This 35-kb chromosomal region
encodes several loci that are required for LA and/or FAS
activity of the A/E-causing bacterial species (EHEC, EPEC
[17], Hafnia alvei [2], and Citrobacter freundii biotype 4280 [38,
39]). Whether B2F1 or other O91:H21 EHEC isolates encode
all or part of the LEE locus is currently under investigation.
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The shorter fusion, RVHdHisEae, also complemented 8624eaeD10, a finding which implies that the region(s) of intimin
that binds the bacterium to the epithelial cell is not in the
amino-terminal one-third of the molecule. The reported homology between EPEC intimin and the invasin protein of Yersinia pseudotuberculosis extends to EHEC intimin and invasin
(17, 51). Invasin is the major protein involved in the penetration of intestinal epithelial cells by Y. pseudotuberculosis (12,
13, 15) and has a pivotal role in the initiation of infection by Y.
enterocolitica (34). Overall, the EHEC intimin and invasin predicted amino acid sequences are 31% identical and 51% similar (51). The carboxyl termini of intimin and invasin are the
most divergent regions between the two proteins. The carboxyl-terminal 192 amino acids of invasin comprise the receptor
binding domain (21–23). Isberg and Leong (14) identified
members of the b1 family of integrins as the cellular receptors
for invasin. The aspartate residue at position 911, critical for
integrin binding by invasin (23), is absent in intimin, but two
cysteine residues essential for binding of invasin to its integrin
receptor (22) are shared by the intimins from all four of the
A/E-promoting bacteria (8). Frankel et al. (8) demonstrated by
use of MBP fusions that the C-terminal 280 amino acids of
intimin from EPEC, EHEC, H. alvei, or C. freundii 4280, although somewhat different from one another at the amino acid
level, were capable of binding and mediating the attachment of
staphylococci to HEp-2 cells. The purified MBP-invasin fusion
proteins were also able to bind HEp-2 cells. However, the
patterns of attachment of the isolated MBP-intimins were different from the pattern demonstrated for the MBP-invasin
fusion protein (8). These investigators did not explore the
potential nucleation of F-actin as a result of the binding of the
intimin carboxyl domain to the HEp-2 cells.
The rabbit and mouse antisera raised against the longer
intimin fusion protein recognized EHEC intimin as well as
EPEC intimin. These data confirm the findings of Louie et al.
(25), who found that antisera raised against an intimin–glutathione-S-transferase fusion protein recognized an OMP expressed by EHEC of various serogroups and EPEC. However,
the capacity of the antibodies against the intimin–glutathioneS-transferase fusion to block adherence to HEp-2 cells was not
demonstrated in that analysis. In the present study, the antiintimin antibodies generated against the longer fusion protein
were capable of blocking the adherence of wild-type EHEC
O157:H7 to HEp-2 cells. Our anti-intimin antisera together
with the histidine fusions created for purification of intimin will
be used as tools for further structure-function analysis of this
EHEC adhesin.
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